Sugi Predict

Sugi Predict / Targets / PDE12

PDE12

2',5'-phosphodiesterase 12 · Q6L8Q7 · PDE12 on Sugi Atlas →

3 patent compounds predicted against PDE12, 2 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29446571 SCHEMBL29446571 1.00 2/20
SCHEMBL30357429 SCHEMBL30357429 1.00 2/20

Clinical trials — most relevant to PDE12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker PHASE4UNKNOWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction PHASE3COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) PHASE3COMPLETED
Efficacy and Safety of UGN-101 in Recurrent Patients PHASE3WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) PHASE2COMPLETED
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease PHASE1COMPLETED
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Endurance Performance at Altitude nanCOMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. nanUNKNOWN
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice nanNOT_YET_RECRUITING
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE12 binder may also engage these)

ProteinNameSimilarity
Q3TIU4 — 1.000 Q3TIU4 →
Q6AXQ5 — 1.000 Q6AXQ5 →
Q08DF7 — 1.000 Q08DF7 →
Q24239 — 0.991 Q24239 →
ELP1 Elongator complex protein 1 0.988 landscape →
KAT8 Histone acetyltransferase KAT8 0.988 landscape →
A7YWI9 — 0.987 A7YWI9 →
Q8K337 — 0.987 Q8K337 →
D3ZEY4 — 0.987 D3ZEY4 →
F4IDQ6 — 0.987 F4IDQ6 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.987 landscape →
Q5BJS0 — 0.986 Q5BJS0 →
Q2QMG2 — 0.986 Q2QMG2 →
KDM5B Lysine-specific demethylase 5B 0.986 landscape →
Q7TT37 — 0.986 Q7TT37 →
Q8VHU4 — 0.986 Q8VHU4 →
B4I8G2 — 0.986 B4I8G2 →
Q9VZS6 — 0.986 Q9VZS6 →
A8XU68 — 0.986 A8XU68 →
O55207 — 0.986 O55207 →
F4J8C6 — 0.986 F4J8C6 →
Q5XJA0 — 0.985 Q5XJA0 →
B4QI55 — 0.985 B4QI55 →
Q9W1V1 — 0.985 Q9W1V1 →
KDM5D Lysine-specific demethylase 5D 0.985 landscape →
A1L251 — 0.985 A1L251 →
Q8LI34 — 0.985 Q8LI34 →
Q04199 — 0.985 Q04199 →
Q8CHC4 — 0.985 Q8CHC4 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.985 landscape →